Emerald Advisers Portfolio holdings
Emerald Advisers is an investment adviser that puts client money mainly in U.S. stocks, with growth strategies for small, mid-sized and mixed-size companies and a separate small cap value strategy. Its team does its own bottom-up research to find under-researched companies, and spends much of its time on the road meeting managers and touring facilities. Kenneth Mertz has been its chief investment officer and president since 1992. Emerald Advisers belongs to Emerald Asset Management PA, LLC and in turn owns Emerald Mutual Fund Advisers Trust, which advises the Emerald mutual funds. Its clients include institutions, governments, trusts, estates, charities and high net worth individuals.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$36.7M |
| 2 |
Replimune Group
REPL
|
+$25.8M |
| 3 |
Red Violet
RDVT
|
+$22M |
| 4 |
AXT Inc
AXTI
|
+$20.2M |
| 5 |
NeoGenomics
NEO
|
+$19.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Modine Manufacturing
MOD
|
+$39.7M |
| 2 |
Synaptics
SYNA
|
+$37.1M |
| 3 |
Rambus
RMBS
|
+$33.5M |
| 4 |
TTM Technologies
TTMI
|
+$28.1M |
| 5 |
Mirion Technologies
MIR
|
+$24.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.39% |
| 2 | Healthcare | 27.18% |
| 3 | Industrials | 18.59% |
| 4 | Financials | 8.67% |
| 5 | Consumer Discretionary | 7.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
DELISTED
Bowman Consulting
BWMN
| – | – |
-20,198
| Closed | -$590K | – |
|
227
Coastal Financial
CCB
$653M
| – | – |
-216,333
| Closed | -$16.8M | – |
|
228
Collegium Pharmaceutical
COLL
$766M
| – | – |
-1,049
| Closed | -$38K | – |
|
229
Carpenter Technology
CRS
$14.8B
| – | – |
-607
| Closed | -$374K | – |
|
230
Deckers Outdoor
DECK
$11.6B
| – | – |
-3,641
| Closed | -$362K | – |
|
231
Genius Sports
GENI
$1.65B
| – | – |
-86,250
| Closed | -$523K | – |
|
232
Hims & Hers Health
HIMS
$4.68B
| – | – |
-608,509
| Closed | -$21.1M | – |
|
233
Houlihan Lokey
HLI
$10.1B
| – | – |
-345
| Closed | -$46.3K | – |
|
234
HubSpot
HUBS
$10.5B
| – | – |
-1,153
| Closed | -$210K | – |
|
235
Louisiana-Pacific
LPX
$5.3B
| – | – |
-605
| Closed | -$47.6K | – |
|
236
Madrigal Pharmaceuticals
MDGL
$10B
| – | – |
-70
| Closed | -$37.6K | – |
|
|
237
Mirion Technologies
MIR
$4.36B
| – | – |
-1,364,780
| Closed | -$24.5M | – |
|
238
Definium Therapeutics
DFTX
$4.52B
| – | – |
-178,751
| Closed | -$8.41M | – |
|
239
Micron Technology
MU
$879B
| – | – |
-77
| Closed | -$88.9K | – |
|
240
Perella Weinberg Partners
PWP
$1.11B
| – | – |
-27,567
| Closed | -$440K | – |
|
|
241
Rambus
RMBS
$9B
| – | – |
-252,693
| Closed | -$33.5M | – |
|
242
Latham Group
SWIM
$975M
| – | – |
-83,582
| Closed | -$541K | – |
|
|
243
Synaptics
SYNA
$4.68B
| – | – |
-298,552
| Closed | -$37.1M | – |
|
244
LendingTree
TREE
$512M
| – | – |
-334,702
| Closed | -$14.8M | – |
|
245
Visteon
VC
$1.99B
| – | – |
-162,419
| Closed | -$16.1M | – |
|
246
Flutter Entertainment
FLUT
$14.3B
| – | – |
-2,704
| Closed | -$276K | – |
|
247
Metallus
MTUS
$722M
| – | – |
-366,351
| Closed | -$6.85M | – |
|
248
Flowco Holdings
FLOC
$936M
| – | – |
-382,062
| Closed | -$8.15M | – |
|
249
Heartflow Inc
HTFL
$5.15B
| – | – |
-154,196
| Closed | -$4.52M | – |
|
250
Lumexa Imaging Holdings
LMRI
$1.47B
| – | – |
-24,441
| Closed | -$276K | – |
|
Similar funds
Emerald Advisers's Q3 2026 Portfolio in Review
As of Q3 2026, Emerald Advisers held 252 positions worth $3.64B, down 14% from $4.25B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Emerald Advisers's Q3 2026 filing shows 15 new, 93 increased, 100 reduced and 28 closed positions. Its largest new stake was Praxis Precision Medicines: 110,764 shares worth $32.3M. The largest sale was Modine Manufacturing, an estimated $39.7M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 27% a quarter earlier, followed by Healthcare and Industrials.
- Emerald Advisers's largest Q3 2026 buy was Praxis Precision Medicines: 110,764 shares worth $32.3M.
- Emerald Advisers added most to MaxLinear in Q3 2026, an estimated $13.7M increase.
- Emerald Advisers's biggest Q3 2026 reduction was Modine Manufacturing, cutting an estimated $39.7M.
- Emerald Advisers fully exited Synaptics in Q3 2026, selling an estimated $37.1M.
- Emerald Advisers's ten largest holdings make up 18% of its $3.64B portfolio in Q3 2026.
- Emerald Advisers opened 15 new positions and closed 28 in Q3 2026.
- Emerald Advisers's portfolio value fell 14% quarter-over-quarter to $3.64B.
Based on Emerald Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.